SCHEMBL29460313

SCHEMBL29460313

O=C(NC12CC(C(F)(F)F)(C1)C2)c1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.52
▸ CES2 O00748 1/20 0.43
▸ CES1 P23141 1/20 0.43
▸ TAS1R3 Q7RTX0 1/20 0.41
▸ TAS1R1 Q7RTX1 1/20 0.41
▸ TAS1R2 Q8TE23 1/20 0.41
▸ STS P08842 1/20 0.40
▸ KCNQ3 O43525 5/20 0.40
▸ KCNQ2 O43526 5/20 0.40
▸ KCNQ5 Q9NR82 1/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ HSD11B1 P28845 1/20 0.38
▸ CHRNA1 P02708 1/20 0.38
▸ CHRNG P07510 1/20 0.38
▸ CHRNB1 P11230 1/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ CHRNB4 P30926 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31046923 0.83 IDO1 (0.46) IDO1TRPA1NPC1RAB9A
SCHEMBL29460291 0.81 HDAC1 (0.51) IDO1CES2CES1NPC1RAB9A
SCHEMBL24118369 0.80 IDO1 (0.46) IDO1CES2CES1TAS1R3TAS1R1
SCHEMBL29460215 0.80 KDM4E (0.49) CES2CES1NPC1CASP3RAB9A
SCHEMBL23141420 0.78 FAAH (0.53) IDO1CES1NPC1CASP3RAB9A
SCHEMBL29460251 0.77 NPSR1 (0.52) CES2TAS1R3TAS1R1TAS1R2LMNA
SCHEMBL24118372 0.76 IDO1 (0.49) IDO1CES2CES1TAS1R3TAS1R1
SCHEMBL29460292 0.75 TRPV1 (0.49) NPC1RAB9A
SCHEMBL23877640 0.75 IDO1 (0.39) IDO1
SCHEMBL21496341 0.74 IDO1 (0.53) IDO1CES2CES1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
CN-118791407-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-10-18 — — CN disclosed
CN-118638096-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-09-13 — — CN disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 — — CN disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B IDO1 3017/4885CES2 247/4885CES1 1305/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B IDO1 3017/4885CES2 247/4885CES1 1305/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 IDO1 3639/4885CES2 526/4885CES1 184/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B IDO1 3017/4885CES2 247/4885CES1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback